Mastermind Genomic Search Engine Identifies Approved and Off-Label Treatments Found Across the Medical Literature
ANN ARBOR, Mich. (PRWEB) April 28, 2020
Genomenon® announced today that the latest release of the Mastermind® Genomic Search Engine includes the ability to search by therapy. Mastermind users can now query the comprehensive database of genomic evidence for over 180,000 drugs, therapies, and other interventions.
This new offering furthers Genomenon’s ability to catalogue a complete dataset of all “Genomic Associations” supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment cancer and other genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since added ACMG/AMP classification, phenotypes, and now therapies. Each new component of association data increases the power of Mastermind to allow users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence.
Searching by therapy provides significant value for oncologists making decisions on third-line therapies, where approved drugs or clinical trials are no longer effective for a cancer patient. Finding a comprehensive list of all therapies in the medical research tied to a cancer patient’s genetic make-up is invaluable for treating these late-stage cancer patients.
The new search capability is also highly useful for clinicians making diagnostic and treatment decisions for patients with rare diseases. There are currently less than 800 FDA approved therapies for over 7,000 rare diseases, leaving many patients without an approved treatment option. In these cases, clinicians are required to scour the medical literature to find therapies associated with the patient’s genetic profile; a time-consuming and often fruitless task.
About Genomenon
Genomenon is a genomic health IT company that connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.
The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.
Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.
Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.
For more information, visit Genomenon.com.
For the original version on PRWeb visit: https://www.prweb.com/releases/genomenons_mastermind_now_finds_therapies_associated_with_genetic_drivers/prweb17078524.htm